AVEO Pharmaceuticals, Inc.

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

January 4, 2007

AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio

BG Medicine, Inc.

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

January 30, 2007

BG Medicine today announced the initiation of a multi-year research project, funded by Merck, AstraZeneca and Philips Medical, aimed at better understanding high risk plaque in heart attack and stroke.  The project will harness BGM’s systems biology measurement approaches along with state-of-the art medical imaging techniques to identify new approaches for the detection and treatment of vulnerable patients.

Epitome Biosystems

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

January 31, 2007

Waltham, MA, and Madison, WI, January 31, 2007 – Epitome Biosystems and EMD Biosciences Inc. announced today the successful completion of a collaboration to develop multiplex assays to measure phosphorylation of cell signaling proteins using Epitome’s EpiTag™ technology. Epitome developed custom antibody and peptide reagents to enable quantitative protein measurements of selected targets for EMD Biosciences. This completes the first commercial partnership for Epitome.

Adnexus Therapeutics

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

February 2, 2007

Angiogenesis Inhibitor, CT-322, Shows Biological Activity at First Dose Level Tested

Helicos BioSciences Corporation

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

February 9, 2007

The company’s researchers have developed proprietary nucleotide-polymerase formulations that enable sequencing through homopolymers.

VisEn Medical, Inc.

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

February 8, 2007

Woburn, MA (February 8, 2007) -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that Erik Wallden has joined the company’s Board of Directors. Previously, Mr. Wallden served as the President and CEO of Biacore International AB, which was sold after a successful turnaround to GE Healthcare in September, 2006.

Epitome Biosystems

Epitome Biosystems Expands Senior Management Team

Epitome Biosystems Expands Senior Management Team

February 13, 2007

Jeffrey Radding Draws on Pharmaceutical Experience to Lead Research and Development

Waltham, MA, February 13, 2007 – Epitome Biosystems, a biotechnology company focused on innovative protein measurement systems, announced today the appointment of Jeffrey Radding, Ph.D., as Vice President, Research & Development. Dr. Radding joins the Company from Eli Lilly, where he led the Platform Biology Group in evaluating and implementing cell signaling approaches for drug discovery across multiple therapeutic areas.

Mascoma Corporation

Flagship Highlighted in CNBC Article on Green Technology

Flagship Highlighted in CNBC Article on Green Technology

February 13, 2007

Flagship General Partner Jim Matheson was recently interviewed and quoted in a CNBC web article about Venture Capital invesment in technolgies for alternative energy, which also highlights portfolio company Mascoma.

Green Technology Revs Up Venture Capitalists
By Scott Reeves | 13 Feb 2007 | 03:09 PM
cnbc.com

© 2007 CNBC, Inc. All Rights Reserved

The smart money sees a green future in alternative technology.

Black Duck Software, Inc.

Black Duck Software Closes $12 Million in Third Round Financing

Black Duck Software Closes $12 Million in Third Round Financing

February 14, 2007

Software Compliance Management Visionary and Provider of Industry’s Most Widely Used Solutions Raises Funds to Power Global Expansion, Further Broaden Product Line

LS9

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

February 14, 2007

Academic and Industry Leaders Pursue Industrial Applications of Synthetic Biology